MCMing Cai

Ming Cai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ming Cai has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Ming Wang

    Department of Urology, the Second Affiliated Hospital, Zhejiang University, School of Medicine

    3 shared publications
  • Zhenan Zhang

    Department of Urology, the Second Affiliated Hospital, Zhejiang University, School of Medicine

    3 shared publications
  • An He

    Department of Urology, the Second Affiliated Hospital, Zhejiang University, School of Medicine

    2 shared publications
  • Bohan Wang

    Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    2 shared publications
  • Jiaju Xu

    Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China

    2 shared publications
  • Jiaming Wen

    Department of Urology, Zhejiang University, The Second Affiliated Hospital of Zhejiang University, China

    2 shared publications

Latest Publications

  • Open Access

    Single-cell transcriptomic landscape of metabolic reprogramming in kidney allograft rejection

    by Zhenan Zhang, Yi Zheng, Long Zheng, An He, Juntao Chen, Jinyu Luo, Ming Wang, Ming Cai

    Introduction: Chronic rejection remains a major barrier to long-term survival after renal transplantation. However, our understanding of the transcriptional programs and metabolic alterations that shape the functions of human kidney cell populations during rejection is still limited. Objectives: To generate a comprehensive, cell type–specific transcriptomic map of metabolic states in healthy and transplanted human kidney samples. Methods: We performed single-cell RNA sequencing on 33 kidney samples, constructing an atlas comprising 82,661 cells. Results: Analysis of average metabolic pathway activity across cell subpopulations revealed distinct metabolic profiles. These differences provided insights into both unique abnormalities and shared features underlying various rejection states. We identified downregulation of mitochondrial programs in multiple non-proximal tubular cell populations compared with their counterparts in healthy kidneys. In contrast, both proximal tubular (PT) cells and T cells exhibited relatively elevated oxidative phosphorylation-related transcriptional scores, though the mechanisms driving this shift were specific to cell type and rejection status. Additionally, rejection-associated macrophages demonstrated altered amino acid metabolism, accompanied by enhanced IL-1 signaling. Conclusion: This single-cell atlas, together with a metabolically based stratification of chronic kidney transplant rejection, offers novel insights into the heterogeneous nature of rejection and provides valuable guidance for the development of targeted therapies.

  • Open Access

    Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma

    by Jiaju Xu, Jinming Xu, Yichang Shu, Qi Huangfu, Letian Shen, Jingchao Wei, Xuhong He, Chengfang Sun, Juntao Chen, Linsong Tang, et al.


  • Open Access

    GRK5 as a Novel Therapeutic Target for Immune Evasion in Testicular Cancer: Insights from Multi-Omics Analysis and Immunotherapeutic Validation

    by Congcong Xu, Qifeng Zhong, Nengfeng Yu, Xuqiang Zhang, Kefan Yang, Hao Liu, Ming Cai, Yichun Zheng

    Background: Personalized anti-tumor therapy that activates the immune response has demonstrated clinical benefits in various cancers. However, its efficacy against testicular cancer (TC) remains uncertain. This study aims to identify suitable patients for anti-tumor immunotherapy and to uncover potential therapeutic targets in TC for the development of tailored anti-tumor immunotherapy. Methods: Consensus clustering analysis was conducted to delineate immune subtypes, while weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, and support vector machine (SVM) algorithms were employed to evaluate the potential efficacy of anti-tumor immunotherapy. Candidate immunotherapy targets were systematically identified through multi-gene panel analyses and subsequently validated using molecular biology assays. A prioritized target emerging from cellular screening was further evaluated for its capacity to potentiate anti-tumor immunity. The therapeutic efficacy of this candidate was rigorously confirmed through a comprehensive suite of immunological experiments. Results: Following systematic screening of five candidate genes (WNT11, FAM181B, GRK5, FSCN1, and ECHS1), GRK5 emerged as a promising therapeutic target for immunotherapy based on its distinct functional and molecular associations with immune evasion mechanisms. Cellular functional assays revealed that GRK5 knockdown significantly attenuated the malignant phenotype of testicular cancer cells, as evidenced by reduced proliferative capacity and invasive potential. Complementary immunological validation established that specific targeting of GRK5 with the selective antagonist GRK5-IN-2 disrupts immune evasion pathways in testicular cancer, as quantified by T-cell-mediated cytotoxicity. Conclusions: These findings position GRK5 as a critical modulator of tumor-immune escape, warranting further preclinical exploration of GRK5-IN-2 as a candidate immunotherapeutic agent.


  • Open Access

    ALKBH5 induces macrophage activation to promote renal fibrosis via Retnla

    by Long Zheng, Wenjun Gao, Zhenan Zhang, An He, Qi Huangfu, Jinyu Luo, Ming Wang, Juntao Chen, Ming Cai

    Renal fibrosis is a common pathological endpoint of various chronic kidney diseases. Macrophages play an important role in the pathophysiological process of renal fibrosis. However, the exact function and molecular mechanism of macrophages during renal fibrosis remain unclear. In this study, we found an increased expression of RNA demethylase AlkB Homolog 5 (ALKBH5) in macrophages from the mice with unilateral ureteral obstruction (UUO) and TGF-β treatments bone marrow-derived macrophages. Macrophage-specific ALKBH5 knockout could significantly alleviate renal fibrosis in UUO mice and decrease the infiltration of macrophages in the kidneys. Further studies showed that ALKBH5 deficiency reduced M2a macrophage polarization and the expression of TGF-β1, Arg1, and CD206 both in vivo and in vitro. RNA sequencing indicated that Resistin-like alpha (Retnla) was the downstream target of ALKBH5, and treatment with recombinant Retnla abrogated the effect of ALKBH5 deficiency on renal fibrosis. We conclude that ALKBH5-dependent regulation of macrophage and kidney fibrosis progression through Retnla represents a novel strategy for patients with chronic kidney disease.


  • Mechanosensitive Ca 2+ channel TRPV1 activated by low‐intensity pulsed ultrasound ameliorates acute kidney injury through Notch1‐Akt‐ eNOS signaling

    by Qi Huangfu, Jun Zhang, Jiaju Xu, Jinming Xu, Zhangcheng Yang, Jingchao Wei, Liuqing Yang, Yichang Shu, Chengfang Sun, Bohan Wang, et al.

    Acute Kidney Injury (AKI) is a significant medical condition characterized by the abrupt decline in kidney function.Low‐intensity pulsed ultrasound (LIPUS), a non‐invasive therapeutic technique employing low‐intensity acoustic wave pulses, has shown promise in promoting tissue repair and regeneration. A novel LIPUS system was developed and evaluated in rat AKI models, focusing on its effects on glomerular filtration rate (GFR), blood urea nitrogen (BUN), serum creatinine (SCr), and the Notch1‐Akt‐eNOS signaling pathway. The results demonstrated that LIPUS treatment improved GFR, BUN, SCr levels, and renal pathology in AKI rats. In vitro experiments using HUVEC cells revealed that LIPUS stimulation promoted angiogenesis, cell migration mechanically‐dependent calcium ion influx, which was partially attenuated by TRPV1 knockdown. RNA sequencing analysis indicated LIPUS‐induced activation of the Notch pathway, phosphorylation of Akt and eNOS. Furthermore, inhibition or genetic silencing of Notch1 abolished the beneficial effects of LIPUS on angiogenesis, renal function, and Akt‐eNOS phosphorylation in both cells and AKI rats. These findings suggest that LIPUS‐induced calcium influx promotes Akt‐eNOS phosphorylation, nitric oxide (NO) production, angiogenesis, and improved renal function in AKI via Notch1‐Akt‐eNOS signaling, positioning LIPUS as a promising therapeutic strategy for AKI by targeting vascular regeneration.


  • Open Access

    Tacrolimus Maintains the Balance of Neutrophil Extracellular Traps by Inducing DNA Methylation of Neutrophils to Reduce Immune Rejection

    by Liang Xu, Ming Cai

    Immune rejection is a significant concern in organ transplantation, as it can lead to damage to and failure of the transplanted organ. To prevent or treat immune rejection, transplant recipients are commonly administered immunosuppressive drugs. Tacrolimus (FK506) is a widely used immunosuppressive drug in organ transplantation. The excessive formation of neutrophil extracellular traps (NETs) can contribute to inflammation and tissue damage. Although NETs play an antimicrobial role, their overproduction can be harmful. To investigate the mechanism by which FK506 suppresses immune rejection, we utilized HL-60 cells, which were differentiated into neutrophils using DMSO and induced to form NETs with phorbol myristate acetate (PMA), a very efficient and frequently used drug for inducing NET formation. By comparing pre- and post-treatment with FK506, we examined whether FK506 affects the formation of NETs. Various experimental techniques were employed, including confocal imaging for visualizing cell NETs, qPCR and Western blotting for gene and protein expression analyses, ELISAs for protein content detection, and LC-MS/MS for methylation detection. In our study, we discovered that FK506 can enhance DNA methylation, which likely contributes to the reduction in NETs. Genes and proteins related to methylation, namely, DNMT3B and TET3, exhibited significant correlations with methylation. Consistent changes in both genes and proteins suggest that DNMT3B and TET3 are key factors that are influenced by FK506, resulting in enhanced DNA methylation and the potential inhibition of PMA-induced NET production. In summary, we have identified a novel mechanism by which FK506 inhibits NET production through the enhancement of DNA methylation. This finding highlights a new aspect of FK506′s immunosuppressive effect. Our results provide valuable insights for clinical research, immunosuppression, and organ preservation strategies.


  • Open Access

    Tacrolimus maintains the balance of NETs by inducing DNA methylation of neutrophils to reduce immune rejection

    by Liang Xu, Ming Cai

    Background The immune rejection is a major concern in organ transplantation and can cause damage to the transplanted organ and ultimately lead to its failure. To prevent or treat immune rejection, transplant recipients are typically given immunosuppressive drugs to suppress their immune system. Tacrolimus is an immunosuppressive drug that is commonly used to prevent or treat immune rejection in organ transplantation. NETs formation and function in innate immunity and inflammation. NETs play an antimicrobial role, but excessive NETs are harmful and can cause inflammation and tissue damage. Methods To clarify the mechanism by which tacrolimus suppresses immune rejection, we used HL-60 cells, induced them to become neutrophils with DMSO, and then induced NETs with PMA. By comparing the changes before and after treatment with tacrolimus, we elucidated whether tacrolimus can change NETs formation. Results In this experiment, we found that tacrolimus can increase DNA methylation, which may be an important reason for the reduction of NETs by tacrolimus, as DNA methylation can stabilize DNA structure, making DNA better able to maintain its own structure. More research is needed to fully understand the relationship between DNA methylation, NETs formation, and immune rejection in organ transplantation, and to determine the potential therapeutic use of drugs that modulate DNA methylation or NETs. Conclusions In conclusion, we have found for the first time that tacrolimus can inhibit the production of NETs by enhancing the DNA methylation of cells, thereby exerting a better immunosuppressive effect. This may be a new mechanism for tacrolimus. We use this mechanism to provide new guidance for clinical research and immunosuppression and rehabilitation in the process of organ inhibition.